The Age of Orphans
Orphan medicines are available for a larger number of diseases and patients than ever before.

Orphan medicines are available for a larger number of diseases and patients than ever before.
Are the incentive mechanisms for orphan drug development working as they should?
Before we can consider ways to address excessive pricing for orphan drugs, we must first diagnose the underlying problem.
What are the most pressing priorities for developing new drugs for rare diseases, and how can legal research help meet these needs?